Skip to main content
Blood Advances logoLink to Blood Advances
. 2024 Jun 1;8(11):2650. doi: 10.1182/bloodadvances.2024013366

Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897.

PMCID: PMC11200031  PMID: 38809539

Page 5892: There is an error in the footnote of Table 1 regarding the description of the possible score range of the SF-12 mental component score (MCS) and physical component summary (PCS). In the article, the score range for the MCS and PCS is stated to be 0 to 100. These 2 measures are actually reported on a T-score metric, which has a mean of 50 and standard deviation of 10. In the Table 1 footnote, “Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning” should read “Scores are on a T-score metric with a mean of 50 and a standard deviation of 10, referenced to a US general population.” Similarly, in the first paragraph on this page, “A patient’s total score could range from 0 (worst health) to 100 (best health), with changes ≥3.9 and 2.8 being considered as CICs in CAD for PCS and MCS, respectively.18-20” should read “A patient’s PCS and MCS scores are on a T-score metric, with a mean of 50 and a standard deviation of 10, referenced to the US general population, with changes ≥3.9 and 2.8 being considered as CICs in CAD for PCS and MCS, respectively.18-20


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES